RecruitingNot Applicable

Identify microRNAs in Cachexia in Pancreatic Carcinoma

United States100 participantsStarted 2022-12-07

Plain-language summary

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female patient, who is ≥ 18 years old at the time of informed consent.
✓. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
✓. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
✓. Ability to provide written informed consent and HIPAA authorization.

Exclusion criteria

✕. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
✕. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

What they're measuring

Proportion of African American pancreatic cancer patients with weight loss and cachexia.

Timeframe: 1 - 12 months

Trial details

NCT IDNCT05275075

SponsorUniversity of Oklahoma

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-01

Contact for this trial

Lead Nurse

405.271.8777 scc-iit-office@ouhsc.edu

View on ClinicalTrials.gov More Resectable Pancreatic Adenocarcinoma trials